Medicare Part D GLP-1 coverage

Medicare Part D coverage at a glance

Coverage details

Medicare historically excluded weight-loss drugs by statute. CMS guidance has expanded coverage when GLP-1s are prescribed for FDA-approved indications other than weight loss alone — including cardiovascular risk reduction (Wegovy) and obstructive sleep apnea (Zepbound).

Tips for Medicare Part D members

If you have a qualifying secondary indication, this is the pathway to coverage. Talk to your prescriber about whether your case meets the FDA-approved sub-indication.

Prior authorization criteria (typical)

• BMI ≥30, OR BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Documented prior weight-loss attempts
• Plan to continue clinical follow-up while on therapy

Your prescribing clinician's office handles the prior authorization submission. Approval timelines vary from 24 hours to 2 weeks depending on the carrier.

If Medicare Part D denies coverage

If your prior authorization is denied or your plan excludes weight-loss drugs, you have three primary options:

1. Appeal the denial with additional clinical documentation. Many denials are reversed on appeal with proper diagnosis coding and history.
2. Switch to compounded GLP-1s through a reputable telehealth provider — typically $199–$499/month vs $1,000+ for brand-name. See our provider rankings.
3. Apply for manufacturer copay programs. Novo Nordisk and Eli Lilly run patient-assistance programs with eligibility limits.

Frequently asked questions

Other carriers